The lysine methyltransferase NSD2 is overexpressed and carries gain-of-function mutations in a number of different cancers, making it an attractive therapeutic target. However, no specific small molecule inhibitors have been identified for this enzyme, responsible for depositing the H3K36me2 mark on histones. A new study reports a robust platform for high-throughput screening (HTS) assays to facilitate this discovery.
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Epigenetic modifications are patterns of posttranslational modifications (such as methylation or acetylation) found on histone tails, commonly referred to as the "histone code." These modifications are installed, removed, and read out by diverse molecules to effect biological outcomes (1) . Importantly, these molecules are often mutated or misregulated in diseases, including cancer, which manifests itself as alterations to the histone code. For example, mutations of the methyltransferases EZH2 and NSD2, including those causing gain-of-function amino acid substitutions, like increased activity or altered specificity, have been linked to tumorigenesis (2). These "epimutations" can theoretically be reversed by chemotherapeutic intervention, making the concept of epigenetic therapy exceptionally appealing. There are two primary ways to block an epigenetic signaling pathway: either inhibit the enzyme that adds the mark or inhibit the effector that reads it. Toward that end, drug discovery efforts for EZH2 have been successful. However, as yet, no potent and selective small molecule inhibitors of NSD2 have been identified.
NSD2 is responsible for depositing the bulk of the histone H3K36me2 mark. Increased levels of this mark, caused by elevated NSD2 activity, are observed in different cancer types and result in the transcriptional activation of normally silenced genes (3) . In a cancer setting, NSD2 activity has been shown to be up-regulated in three ways. First, a chromosomal translocation can generate a fusion between NSD2 and the immunoglobulin heavy chain (IgH), which places the NSD2 gene under the control of the IgH enhancer, resulting in its overexpression (4) . Second, NSD2 can be up-regulated at the transcriptional level, as seen in a large variety of human tumors (5) . Third, point mutations that produce the amino acid changes E1099K or T1150A result in a hyperactive enzyme (6, 7) . Ectopic expres-sion of WT NSD2 or these activating mutants causes elevated K3K36me2 levels and promotes oncogenic transformation, whereas knockdown of this enzyme in certain cell lines reduces proliferation and tumorigenesis. Thus, NSD2 is a very good target for drug discovery. Unfortunately, ongoing efforts to identify specific NSD2 inhibitors have largely been unsuccessful, with lead compounds either being weak (LEM-06) or nonspecific (suramin, chaetocin, sinefungin, and BIX-01294) (8) . Progress in this field has been slow in large part because NSD2 requires a nucleosomal substrate and will not efficiently catalyze the methylation of peptides or recombinant histones, which has made the development of HTS 2 challenging (9).
In a recently published study, Coussens et al. (8) will help to address this gap with their development of a battery of orthogonal HTS, using nucleosomes as a substrate, which will likely facilitate the identification and detailed characterization of NSD2 inhibitors. A histone octamer assembles when a tetramer, containing two copies of both H3 and H4, complexes with two H2A/H2B dimers. Once DNA is wrapped around this octamer, it is referred to as a nucleosome. Importantly, in the absence of DNA, the histone octamer is methylated on H4 by recombinant NSD2; in the presence of DNA, the nucleosome is methylated "correctly" on H3 (9) . Thus, the development of HTS using nucleosomes requires more effort than screens using peptides or recombinant protein, but is critical in the search for NSD2 inhibitors. The primary screen they developed used a bioluminescent assay called MTase-Glo, with full-length NSD2 and purified HeLa nucleosomes as the substrate. They also demonstrated that this assay can be used with the NSD2 variants E1099K and T1150A, which should facilitate the identification of selective inhibitors of these two oncogenic forms of NSD2. As a secondary screen, they adapted a homogeneous time-resolved fluorescence (HTRF) assay using recombinant NSD2 and a nucleosomal substrate. When NSD2 methylates a nucleosome, it produces S-adenosyl-L-homocysteine (SAH), and both the MTase-Glo assay and the HTRF assay measure the production of SAH as an indirect gauge of methylation. The authors also implemented a redox cycling assay and an interference compound filter to remove promiscuous or reactive compounds. As a next step, the authors used an additional secondary screening approach, using a radioisotope-based filter-binding HotSpot assay, to directly test the in vitro methylation of nucleosomes. The HotSpot assay is more sensitive than the MTase-Glo and HTRF assays, but of course requires appro- priate facilities and the ability to work with radioisotopes. Finally, a surface plasmon resonance screen was developed using a truncated construct of NSD2 to evaluate the direct binding of the identified compounds to the catalytic domain of the enzyme. With one primary and three secondary assays in hand, the investigators screened a library of over 16,000 compounds; 48 compounds made it through the first two indirect screens and filters, with five selected compounds (DA3003-1, PF-03882845, chaetocin, TC LPA5 4, and ABT-199) evaluated in the final two direct screens. To further characterize these lead compounds, an impressive specificity screen was established using 37 different methyltransferases. The five lead compounds were not very specific for NSD2, nor were they very effective in reducing H3K36me2 levels in U2OS cells. Indeed, for all compounds tested, the reduction in H3K36me2 signal correlated with cytotoxicity. Knockdown of NSD2 does not reduce the proliferation rate of U2OS cells, which suggests that the cytotoxicity observed with these compounds is likely due to off-target effects. Thus, these particular compounds are unlikely to advance further. However, this work does establish a solid primary screening approach for NSD2 inhibitors, along with a notable set of orthogonal/counter/specificity screens to be used for an expanded screen and for use by other investigators.
The efforts by Coussens et al. (8) to develop screens to identify inhibitors of the enzymatic activity of NSD2 will certainly inspire new efforts in molecular discovery. However, NSD2 also harbors a number of domains that can potentially "read" the histone code, including four PHD fingers and two PWWP domains that could also serve as targets. Indeed, its N-terminal PWWP1 domain of NSD2 recognized the same mark that it deposits. Thus, the PWWP1 domain is critical for the recruitment of this enzyme to chromatin and for the propagation of the H3K36me2 mark, as it can read the H3K36me2 mark on one nucleosome and deposit the same mark on an adjacent nucleosome, thus spreading this modification (10) . A small molecule antagonist of the PWWP1 domain of NSD2 may thus function similarly to an inhibitor of its enzyme activity. Efforts toward developing compounds that block PWWP domain reader functions are underway, and a collaboration between Boehringer Ingelheim and the Structural Genomic Consortium (SGC) has recently identified a small molecule probe called BI-9321 that inhibits the PWWP1 domain of NSD3. Although the PWWP1 domains of NSD2 and NSD3 are highly related, and both read the H3K36me2 mark, the BI-09321 chemical probe blocks the binding activity of only the NSD3 PWWP1 domain. Analogs of this compound may display specificity for the NSD2 PWWP1 domain. The BI-09321 compound is currently available to investigators through the SGC (https://www.thesgc.org/node/633667). 3 NSD2 remains a very desirable therapeutic target, and, despite attempts by a number of research groups, no high-quality chemical probes have yet been developed. Using the appropriate nucleosome-based screens developed by Coussens et al. (8) , in conjunction with a larger library of small molecules (larger than 16,000 compounds), it is likely that viable lead compounds that inhibit NSD2 will be discovered.
